Date:3/1/2011

sks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene -206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and will soon be available for sale in the United States.

'/>"/>

SOURCE BioNeutral Group, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
2. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
5. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
6. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
8. Kentucky Hospital Association Solutions Group Outlines Next Steps for BioNeutral Partnership
9. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
10. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
11. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results